Large-scale production of pharmaceutical proteins in plant cell culture-the protalix experience

Yoram Tekoah, Avidor Shulman, Tali Kizhner, Ilya Ruderfer, Liat Fux, Yakir Nataf, Daniel Bartfeld, Tami Ariel, Svetlana Gingis-Velitski, Uri Hanania, Yoseph Shaaltiel

Research output: Contribution to journalReview articlepeer-review

116 Scopus citations


Protalix Biotherapeutics develops recombinant human proteins and produces them in plant cell culture. Taliglucerase alfa has been the first biotherapeutic expressed in plant cells to be approved by regulatory authorities around the world. Other therapeutic proteins are being developed and are currently at various stages of the pipeline. This review summarizes the major milestones reached by Protalix Biotherapeutics to enable the development of these biotherapeutics, including platform establishment, cell line selection, manufacturing process and good manufacturing practice principles to consider for the process. Examples of the various products currently being developed are also presented.

Original languageEnglish
Pages (from-to)1199-1208
Number of pages10
JournalPlant Biotechnology Journal
Issue number8
StatePublished - 1 Oct 2015
Externally publishedYes


  • Enzyme replacement therapy
  • Molecular farming
  • Oral delivery
  • Plant cell culture
  • Protalix Biotherapeutics
  • β-glucocerebrosidase

ASJC Scopus subject areas

  • Biotechnology
  • Agronomy and Crop Science
  • Plant Science


Dive into the research topics of 'Large-scale production of pharmaceutical proteins in plant cell culture-the protalix experience'. Together they form a unique fingerprint.

Cite this